Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases.
Processa is developing VT-7208 in three parallel programs: food allergy and chronic spontaneous urticaria (CSU) in immunology, and relapsing multiple sclerosis (RMS) in neurology, where its CNS-penetrant profile addresses an area of high unmet need. With Phase 1 complete, the company intends to advance all three programs toward Phase 2 proof-of-concept studies, with initial data expected in 2027 and 2028.
